» Articles » PMID: 24092238

MyoD is a Tumor Suppressor Gene in Medulloblastoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2013 Oct 5
PMID 24092238
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

While medulloblastoma, a pediatric tumor of the cerebellum, is characterized by aberrations in developmental pathways, the majority of genetic determinants remain unknown. An unbiased Sleeping Beauty transposon screen revealed MyoD as a putative medulloblastoma tumor suppressor. This was unexpected, as MyoD is a muscle differentiation factor and not previously known to be expressed in cerebellum or medulloblastoma. In response to deletion of one allele of MyoD, two other Sonic hedgehog-driven mouse medulloblastoma models showed accelerated tumor formation and death, confirming MyoD as a tumor suppressor in these models. In normal cerebellum, MyoD was expressed in the proliferating granule neuron progenitors that are thought to be precursors to medulloblastoma. Similar to some other tumor suppressors that are induced in cancer, MyoD was expressed in proliferating medulloblastoma cells in three mouse models and in human medulloblastoma cases. This suggests that although expression of MyoD in a proliferating tumor is insufficient to prevent tumor progression, its expression in the cerebellum hinders medulloblastoma genesis.

Citing Articles

MyoD1 promotes the transcription of BIK and plays an apoptosis-promoting role in the development of gastric cancer.

Wu F, Zhang J, Jiang Q, Li Q, Li F, Li J Cell Cycle. 2024; 23(5):573-587.

PMID: 38701194 PMC: 11135814. DOI: 10.1080/15384101.2024.2348344.


PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth.

Cleveland A, Malawsky D, Churiwal M, Rodriguez C, Reed F, Schniederjan M Acta Neuropathol Commun. 2023; 11(1):8.

PMID: 36635771 PMC: 9838053. DOI: 10.1186/s40478-023-01508-x.


Development of Nystagmus With the Absence of MYOD Expression in the Extraocular Muscles.

Johnson L, Kueppers R, Shen E, Rudell J, McLoon L Invest Ophthalmol Vis Sci. 2021; 62(13):3.

PMID: 34617961 PMC: 8504190. DOI: 10.1167/iovs.62.13.3.


scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.

Ocasio J, Babcock B, Malawsky D, Weir S, Loo L, Simon J Nat Commun. 2019; 10(1):5829.

PMID: 31863004 PMC: 6925218. DOI: 10.1038/s41467-019-13657-6.


Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.

Menyhart O, Gyorffy B Ann Clin Transl Neurol. 2019; 6(5):990-1005.

PMID: 31139698 PMC: 6529984. DOI: 10.1002/acn3.762.


References
1.
Castellino R, De Bortoli M, Lin L, Skapura D, Rajan J, Adesina A . Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer. 2007; 7:127. PMC: 1955450. DOI: 10.1186/1471-2407-7-127. View

2.
Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

3.
Miceli A, Saporita A, Weber J . Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint. Mol Cell Biol. 2011; 32(2):348-64. PMC: 3255786. DOI: 10.1128/MCB.06030-11. View

4.
Kho A, Zhao Q, Cai Z, Butte A, Kim J, Pomeroy S . Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004; 18(6):629-40. PMC: 387239. DOI: 10.1101/gad.1182504. View

5.
Yang Z, Ellis T, Markant S, Read T, Kessler J, Bourboulas M . Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008; 14(2):135-45. PMC: 2538687. DOI: 10.1016/j.ccr.2008.07.003. View